Plus Therapeutics Q2 2024 Adj EPS $(0.71) Misses $(0.53) Estimate
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics (NASDAQ:PSTV) reported a Q2 2024 adjusted EPS of $(0.71), missing the analyst consensus estimate of $(0.53) by 33.96%.
August 14, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Plus Therapeutics reported a Q2 2024 adjusted EPS of $(0.71), significantly missing the analyst consensus estimate of $(0.53) by 33.96%.
The significant miss in EPS compared to analyst expectations is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100